{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-000313","form_type":"8-K","ticker":"COSM","cik":"0001474167","company_name":"Cosmos Health Inc.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.273773+00:00","generated_at":"2026-06-06T20:36:52.060650+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cosmos Health acquires 10 generic drug portfolio for $3.5M from related party","bullets":["Acquired licenses/rights to 10 generic drugs from related party for €3.2M ($3.5M).","Drugs target diabetes, cholesterol, respiratory, cardiac conditions and more.","Manufacturing to occur at Cosmos' wholly-owned subsidiary Cana Laboratories.","Global generic drugs market valued at $411.99B in 2022, projected to $613.34B by 2030.","CEO says acquisition supports transition to full-fledged pharmaceutical company."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-000313","json":"https://secwatch.observer/filing/0001477932-24-000313.json","markdown":"https://secwatch.observer/filing/0001477932-24-000313.md","text":"https://secwatch.observer/filing/0001477932-24-000313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1474167/000147793224000313/0001477932-24-000313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1474167/000147793224000313/cosm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:36:52.060650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}